Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells

被引：0
|
作者：
Amjad Ali
Hema Unnikannan
Jasmin Shafarin
Khuloud Bajbouj
Jalal Taneera
Jibran Sualeh Muhammad
Haydar Hasan
Albert Salehi
Samir Awadallah
Mawieh Hamad
机构：
[1] University of Sharjah,Sharjah Institute for Medical Research
[2] University of Sharjah,Department of Basic Medical Sciences, College of Medicine
[3] University of Sharjah,Department of Clinical Nutrition and Dietetics, College of Health Sciences
[4] Lund University,Department of Clinical science, UMAS, Clinical Research Center
[5] University of Gothenburg,Department of Neuroscience and Physiology, Metabolic Research Unit
[6] University of Sharjah,Department of Medical Laboratory Sciences, College of Health Sciences
来源：
Endocrine | 2022年 / 76卷
关键词：
Metformin; PCSK9; HNF-1α; SREBP2; LDL-cholesterol; LDLR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：543 / 557
页数：14
相关论文
共 50 条
  • [41] EGYPTIAN ASSOCIATION OF VASCULAR BIOLOGY AND ATHEROSCLEROSIS (EAVA) CONSENSUS ON THE USAGE OF PRO PROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS
    Reda, Ashraf
    Elserafy, Ahmed Shawky
    Farag, Elsayed
    Mostafa, Tamer
    Farag, Nabil
    Elbahry, Atef
    Sanad, Osama
    Bendary, Ahmed
    Elkersh, Ahmed
    Attia, Ihab
    Beshay, Morad
    Selim, Mohammed
    Khamis, Hazem
    ATHEROSCLEROSIS SUPPLEMENTS, 2020, 41 : E1 - E1
  • [42] Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention
    Zhu, Yiming M.
    Anderson, Todd J.
    Sikdar, Khokan
    Fung, Marinda
    McQueen, Matthew J.
    Lonn, Eva M.
    Verma, Subodh
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2015, 35 (10) : 2254 - 2259
  • [43] Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
    Metkus, Thomas S.
    Kim, Bo Soo
    Jones, Steven R.
    Martin, Seth S.
    Schulman, Steven P.
    Leucker, Thorsten M.
    FRONTIERS IN MEDICINE, 2022, 9
  • [44] PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) LEVEL IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA IN RUSSIA
    Benimetskaya, Kseniya
    Ragino, Yulia
    Shakhtshneider, Elena
    Makarenkova, Kseniya
    Stakhneva, Ekaterina
    Astrakov, Sergey
    Shchepina, Yulia
    Voevoda, Mikhail
    ATHEROSCLEROSIS, 2017, 263 : E195 - E195
  • [45] Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
    Sun, Huimin
    Meng, Wen
    Zhu, Jie
    Wang, Lu
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2022, 395 (06) : 643 - 658
  • [46] IDENTIFICATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FROM NATURAL PRODUCTS
    Hirata, Hiroshi
    Kontani, Ami
    Takazumi, Koji
    Segawa, Shuichi
    Tsuchiya, Youichi
    ANNALS OF NUTRITION AND METABOLISM, 2017, 71 : 1175 - 1175
  • [47] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy
    Joseph, Lee
    Robinson, Jennifer G.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2015, 58 (01) : 19 - 31
  • [48] Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
    Sharotri, Vikas
    Collier, Daniel M.
    Olson, Diane R.
    Zhou, Ruifeng
    Snyder, Peter M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (23) : 19266 - 19274
  • [49] Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke
    Zhang, Lingling
    Song, Kangping
    Zhu, Mengting
    Shi, Jinling
    Zhang, Huijuan
    Xu, Liang
    Chen, Yingzhu
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2016, 126 (08) : 675 - 680
  • [50] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): Lessons Learned from Patients with Hypercholesterolemia
    Awan, Zuhier
    Baass, Alexis
    Genest, Jacques
    CLINICAL CHEMISTRY, 2014, 60 (11) : 1380 - 1389
12345